Jun. 29 at 10:08 AM
$JUNS Jupiter
$100 Million ALA-002 Licensing Deal
✅ Exclusive, perpetual U.S. licensing rights to ALA-002 under a
$100 million term sheet
✅ Upfront consideration of
$3.33 million, including
$1.50 million cash and
$1.83 million in JUNS shares
✅ Single-digit royalties and development milestone payments tied to ALA-002 progress and commercialization
✅ ALA-002 recognized by FDA as a Novel Chemical Entity, supporting differentiated regulatory profile
✅ ALA-002 engineered for improved cardiovascular safety and reduced abuse liability versus racemic MDMA
✅ Positioning within projected multi-billion-dollar U.S. psychedelic therapeutics market for PTSD, anxiety and depression
